|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF737 |
Gene summary for ZNF737 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF737 | Gene ID | 100129842 |
| Gene name | zinc finger protein 737 | |
| Gene Alias | ZNF102 | |
| Cytomap | 19p12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O75373 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100129842 | ZNF737 | HCC1 | Human | Liver | HCC | 2.39e-18 | 2.37e+00 | 0.5336 |
| 100129842 | ZNF737 | HCC2 | Human | Liver | HCC | 8.12e-29 | 2.44e+00 | 0.5341 |
| 100129842 | ZNF737 | HCC5 | Human | Liver | HCC | 3.48e-26 | 1.70e+00 | 0.4932 |
| 100129842 | ZNF737 | male-WTA | Human | Thyroid | PTC | 1.04e-12 | 1.87e-01 | 0.1037 |
| 100129842 | ZNF737 | PTC01 | Human | Thyroid | PTC | 9.89e-03 | 4.18e-02 | 0.1899 |
| 100129842 | ZNF737 | PTC03 | Human | Thyroid | PTC | 6.94e-04 | 1.80e-01 | 0.1784 |
| 100129842 | ZNF737 | PTC04 | Human | Thyroid | PTC | 7.32e-09 | 1.12e-01 | 0.1927 |
| 100129842 | ZNF737 | PTC05 | Human | Thyroid | PTC | 7.54e-06 | 2.28e-01 | 0.2065 |
| 100129842 | ZNF737 | PTC06 | Human | Thyroid | PTC | 7.62e-07 | 1.74e-01 | 0.2057 |
| 100129842 | ZNF737 | PTC07 | Human | Thyroid | PTC | 5.96e-08 | 2.18e-01 | 0.2044 |
| 100129842 | ZNF737 | ATC13 | Human | Thyroid | ATC | 1.96e-15 | 1.31e-01 | 0.34 |
| 100129842 | ZNF737 | ATC5 | Human | Thyroid | ATC | 1.29e-07 | 1.44e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF737 | SNV | Missense_Mutation | c.817A>G | p.Thr273Ala | p.T273A | O75373 | protein_coding | tolerated(0.05) | benign(0.054) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| ZNF737 | SNV | Missense_Mutation | c.352N>A | p.Glu118Lys | p.E118K | O75373 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| ZNF737 | SNV | Missense_Mutation | c.716N>A | p.Ser239Asn | p.S239N | O75373 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF737 | SNV | Missense_Mutation | c.662N>A | p.Arg221Lys | p.R221K | O75373 | protein_coding | tolerated(0.63) | benign(0.017) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| ZNF737 | deletion | Frame_Shift_Del | c.183delA | p.Lys61AsnfsTer3 | p.K61Nfs*3 | O75373 | protein_coding | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |||
| ZNF737 | SNV | Missense_Mutation | rs782036561 | c.76N>T | p.Arg26Trp | p.R26W | O75373 | protein_coding | deleterious(0.04) | benign(0.02) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ZNF737 | SNV | Missense_Mutation | novel | c.527T>A | p.Ile176Lys | p.I176K | O75373 | protein_coding | tolerated(1) | benign(0) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| ZNF737 | SNV | Missense_Mutation | rs782226892 | c.526A>G | p.Ile176Val | p.I176V | O75373 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| ZNF737 | SNV | Missense_Mutation | novel | c.667C>G | p.His223Asp | p.H223D | O75373 | protein_coding | deleterious(0) | possibly_damaging(0.627) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| ZNF737 | SNV | Missense_Mutation | novel | c.1464N>T | p.Lys488Asn | p.K488N | O75373 | protein_coding | deleterious(0.01) | benign(0.298) | TCGA-VS-A8EC-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |